IDEAYA Biosciences Files for $50 Million IPO to Advance Clinical Development of Small Molecule Oncology Therapies

VCBeat (WeChat Official Account: vcbeat) has learned that on May 22, IDEAYA Biosciences, a biotechnology company headquartered in South San Francisco, announced its initial public offering (IPO) on the Nasdaq Stock Market under the ticker symbol IDYA, aiming to raise $50 million. The company plans to issue 5 million shares at a price of $10 per share. This pricing is significantly below the targeted range of $13 to $15 per share. J.P. Morgan, Citigroup, and Jefferies served as joint book-running managers for this offering.

Headquartered in South San Francisco, California, IDEAYA Biosciences is a precision medicine company focused on oncology, dedicated to developing anticancer drugs by directly targeting oncogenic pathways and leveraging synthetic lethality approaches. The company combines extensive capabilities in identifying and validating translational biomarkers with small-molecule drug discovery to select patient populations most likely to benefit from the targeted therapies under development at IDEAYA.

IDEAYA Biosciences’ preclinical drug portfolio includes compounds that leverage the synthetic lethality approach. This approach exploits genetic interactions to jointly trigger cancer cell death. The company has now entered the ovarian cancer market using this strategy. IDEAYA Biosciences’ precision medicine pipeline features a diverse array of biomarker candidates for various classes of targeted therapies. This pipeline is complemented by a proprietary target discovery platform designed to assess potential synthetic lethal relationships between candidate drug targets and tumor suppressor genes (TSGs).

The company is developing IDE196, a selective protein kinase C (PKC) inhibitor. Originally developed by Novartis, this inhibitor blocks cancer-associated PKC and specifically targets cancers driven by GNAQ or GNA11 gene mutations. In a Phase I clinical trial conducted by Novartis in patients with metastatic uveal melanoma (a type of eye cancer), IDE196 demonstrated favorable tolerability. IDEAYA Biosciences stated that the drug holds promise for broader application across various solid tumors harboring GNAQ or GNA11 mutations or PKC gene fusions.

Currently, IDEAYA Biosciences has obtained a development license from Novartis and has initiated Phase 1/2 clinical trials of IDE196 in patients with solid tumors harboring GNAQ or GNA11 mutations. The study is expected to commence in the second or third quarter of this year. According to the prospectus, the company plans to allocate $27 million to $32 million of its IPO proceeds toward the development of this drug.

According to the prospectus, since its establishment in 2015, IDEAYA Biosciences has raised more than $140 million. Its investors include Celgene, GV, Novartis, and Roche Venture Fund. Prior to the initial public offering, the company’s largest shareholder was 5AM Ventures, which held an 18.7% stake, followed by Canaan Partners with a 15.6% stake.

(Compiled by Li Chengping)